New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Traws Pharma, Inc.

Contributing Author

Recent Articles by Traws Pharma, Inc.

Jan-26	Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza TRAW GlobeNewswire
Jan-13	Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID-Eligible and Ineligible COVID-19 Patients TRAW GlobeNewswire
Dec-17	Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients TRAW GlobeNewswire
Nov-13	Traws Pharma Reports Third Quarter 2025 Results and Business Highlights TRAW GlobeNewswire
Oct-14	Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 TRAW GlobeNewswire
Oct-06	Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives TRAW GlobeNewswire
Aug-18	Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 TRAW GlobeNewswire
Aug-14	Traws Pharma Reports Second Quarter 2025 Results and Business Highlights TRAW GlobeNewswire
Aug-08	Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 TRAW GlobeNewswire
Jun-30	Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions TRAW GlobeNewswire
Jun-03	Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib TRAW GlobeNewswire
May-27	Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness TRAW GlobeNewswire
May-15	Traws Pharma Reports First Quarter 2025 Results and Business Highlights TRAW GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.